Ye Zhen-Nan, Liu Jing-Peng, Wu Ling-Yun, Zhang Xiang-Sheng, Zhuang Zong, Chen Qiang, Lu Yue, Liu Ce-Gang, Zhang Zi-Huan, Zhang Hua-Sheng, Hou Wen-Zhong, Hang Chun-Hua
Department of Neurosurgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, Guangdong Province, China; Department of Neurosurgery, Jinling Hospital, Clinical Medical College of Southern Medical University (Guangzhou), Nanjing 210002, Jiangsu Province, China.
Department of Neurosurgery, Jinling Hospital, Clinical Medical College of Southern Medical University (Guangzhou), Nanjing 210002, Jiangsu Province, China.
Hum Pathol. 2017 May;63:46-52. doi: 10.1016/j.humpath.2016.12.031. Epub 2017 Feb 21.
Glioma is the most common type of malignant neoplasm in the central nervous system, with high incidence and mortality rate. MicroRNAs, as a class of small noncoding RNAs, play an important role in carcinogenesis and correlate with glioma diagnosis and prognosis. In this study, we investigated the microRNA-204 (miR-204) concentration in glioma tissues and its relation to the expression of ezrin and bcl-2 mRNA, as well as its potential predictive and prognostic values in glioma. The concentrations of miR-204 were significantly lower in glioma tissues than in nontumor brain tissues and also were lower in high-grade than in low-grade gliomas (World Health Organization grades III and IV versus grades I and II). The miR-204 concentration was inversely correlated with the ezrin and bcl-2 concentrations. The miR-204 concentration was classified as high or low according to the median value, and low miR-204 correlated with higher World Health Organization grade, larger tumor, and worse Karnofsky performance score. Kaplan-Meier survival analysis demonstrated that patients with low miR-204 expression had shorter progression-free survival and overall survival than patients with high miR-204 expression. In addition, univariate and multivariate analyses showed that miR-204 expression was an independent prognostic feature of overall survival and progression-free survival. In conclusion, our study indicates that miR-204 is downregulated in glioma and may be a biomarker of poor prognosis in patients with this cancer.
胶质瘤是中枢神经系统最常见的恶性肿瘤类型，发病率和死亡率都很高。微小RNA作为一类小的非编码RNA，在肿瘤发生过程中发挥重要作用，并且与胶质瘤的诊断和预后相关。在本研究中，我们调查了胶质瘤组织中微小RNA-204（miR-204）的浓度及其与埃兹蛋白和bcl-2 mRNA表达的关系，以及其在胶质瘤中的潜在预测和预后价值。胶质瘤组织中miR-204的浓度显著低于非肿瘤脑组织，并且高级别胶质瘤（世界卫生组织III级和IV级与I级和II级相比）中的miR-204浓度也低于低级别胶质瘤。miR-204浓度与埃兹蛋白和bcl-2浓度呈负相关。根据中位数将miR-204浓度分为高或低，低miR-204与更高的世界卫生组织分级、更大的肿瘤以及更差的卡氏评分相关。Kaplan-Meier生存分析表明，miR-204表达低的患者无进展生存期和总生存期比miR-204表达高的患者短。此外，单因素和多因素分析表明，miR-204表达是总生存期和无进展生存期的独立预后特征。总之，我们的研究表明miR-204在胶质瘤中表达下调，可能是这种癌症患者预后不良的生物标志物。
